CD5 and cancer: In addition, we predicted the sensitivity of common anti-cancer drugs on prognostic signature, including CCR5 (Fig. 6C), HMOX1 (Fig. 6D), CTSC (Fig. 6E), CD5 (Fig. 6F), BCL3 (Fig. 6G), CDH1 (Fig. 6H), TYROBP and CD38 (Fig. 6I).